Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.

Ejlertsen, BentBarrios, Carlos H.Gokmen, ErhanRobert, NicholasMartinez, NoeliaLink, John S.Morales, SerafinBorrego, Manuel RuizBhandari, ManishRai, YoshiakiLuczak, AdamFujita, TakashiWong, AlvinYao, BinMartin, Miguel2019-10-272019-10-2720180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.15_suppl.549https://hdl.handle.net/11454/30385en10.1200/JCO.2018.36.15_suppl.549info:eu-repo/semantics/closedAccessTiming of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.Conference Object3615WOS:000442916000058Q1